AstraZeneca’s cancer treatment, Lynparaza, has been shown to reduce cancer growth, in its latest clinical trial, and progression in breast cancer caused by the BRCA gene which causes up to 3% of all breast cancers. Both progression and growth of cancers reduced by 42% with few side effects when compared with chemotherapy. BRCA cancers are particularly difficult to treat and many patient choose to undergo a double mastectomy in order to lower chances of BRCA breast cancer progression. Lynparaza is already approved for the treatment of BRCA ovarian cancers. Read the full article here.